Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis

Core Insights - Artelo Biosciences, Inc. announced positive research results for ART26.12, a treatment for psoriasis, showing efficacy comparable to existing immunomodulatory drugs with serious side effects [1][2][3] Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for various conditions, including cancer, pain, and dermatological issues [7] - The company is advancing a portfolio of product candidates aimed at addressing significant unmet medical needs across multiple diseases [7] Product Development - ART26.12 is an orally active small-molecule inhibitor of Fatty Acid Binding Protein 5 (FABP5), which has shown efficacy in preclinical psoriasis models [2][4] - Pre-clinical studies suggest a low toxicological risk for ART26.12, indicating it may be a safer and less costly treatment option for chronic diseases like psoriasis [4] - A Phase 1 Single Ascending Dose study in healthy volunteers has completed enrollment, with data expected to be announced in the current quarter [4][5] Market Potential - Psoriasis affects approximately 2-3% of the global population and is associated with significant quality of life impacts [6] - The global psoriasis market was valued at $27.2 billion in 2024 and is projected to grow to $57.68 billion by 2032 [6]